Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia

The American Journal of Cardiology
Tse-Min LuKai-Min Chu

Abstract

Elevated plasma levels of asymmetric dimethylarginine (ADMA) have been associated with attenuated endothelium-dependent vasodilation in hypercholesterolemic patients. However, whether lowering of plasma cholesterol concentration by hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) can reduce plasma ADMA levels is still not clear. This study was a multicenter, randomized, double-blind, placebo-controlled design including 46 patients with elevated low-density lipoprotein cholesterol levels. Patients were randomized into 2 groups: rosuvastatin 10 mg/day and placebo for 6 weeks. Plasma levels of ADMA, 8-isoprostane (as a marker of oxidative stress), homocysteine, and high-sensitivity C-reactive protein were measured at baseline and 6 weeks later. Endothelial function assessed by flow-mediated vasodilation of the brachial artery was performed in 11 patients in the rosuvastatin group and in 12 in the placebo group. Baseline characteristics of both groups were similar, and the plasma ADMA levels were significantly correlated with 8-isoprostane (r = 0.388, p = 0.008). After 6 weeks of treatment, plasma ADMA levels were significantly reduced in the rosuvastatin group (from 0.60 +/- 0.19 to 0.49 +/- 0.10 micromol/L, p <0.00...Continue Reading

References

Dec 22, 1998·Circulation·M P ReillyG A FitzGerald
Dec 29, 2000·Journal of the American College of Cardiology·R H BögerJ P Cooke
Aug 29, 2001·The American Journal of Cardiology·A G OlssonA Raza
Mar 21, 2002·JAMA : the Journal of the American Medical Association·Markus C StühlingerPhilip S Tsao
Oct 2, 2002·Journal of the American College of Cardiology·Steven P JonesDavid J Lefer
Jan 28, 2003·Journal of Cardiovascular Pharmacology·Hannu PäiväReijo Laaksonen
Jul 16, 2003·Circulation·Mehdi H ShishehborStanley L Hazen

❮ Previous
Next ❯

Citations

May 8, 2007·Cardiovascular Drugs and Therapy·Mika J ThomsonJuan-Carlos Kaski
Oct 14, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hisanori MorimotoHirofumi Makino
Sep 18, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Scott S BilleckeCrystal A Gadegbeku
Apr 13, 2006·Current Opinion in Nephrology and Hypertension·Carmine Zoccali, Jan T Kielstein
Jul 17, 2010·Artificial Organs·Jaromír EiseltSylvie Opatrná
Jul 27, 2010·American Journal of Respiratory Cell and Molecular Biology·Anurag AgrawalBalaram Ghosh
Oct 4, 2005·Clinical Chemistry and Laboratory Medicine : CCLM·Tom Teerlink
Dec 18, 2012·Journal of the American Society of Nephrology : JASN·Neeraj DhaunDavid J Webb
May 14, 2009·Vascular Health and Risk Management·Paolo RubbaMarco Gentile
Aug 1, 2008·Biomarkers in Medicine·Guntram Schernthaner, Katarzyna Krzyzanowska
Nov 3, 2011·Pharmacogenomics·Ping Wang
Oct 31, 2012·International Journal of Molecular Sciences·Luis Aldámiz-Echevarría, Fernando Andrade
Dec 4, 2012·International Journal of Molecular Sciences·Angela SciacquaFrancesco Perticone
Feb 28, 2013·International Journal of Molecular Sciences·Shufen ChenHans Worthmann
Nov 18, 2010·Journal of Atherosclerosis and Thrombosis·Yasuhiro NishiyamaYasuo Katayama
Sep 13, 2008·Journal of Endocrinological Investigation·E SantiniA Solini
Oct 12, 2013·Antioxidants & Redox Signaling·Marios MargaritisCharalambos Antoniades
Jul 6, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Theodoros I Kassimatis, David J A Goldsmith
Jun 25, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Kathleen J ClaesPieter Evenepoel
Sep 30, 2008·Wiener klinische Wochenschrift·Friedrich MittermayerMichael Wolzt
Sep 12, 2007·Expert Opinion on Therapeutic Targets·Konstantinos TziomalosDimitri P Mikhailidis
Apr 22, 2009·Expert Review of Molecular Diagnostics·Njeri Thande, Robert S Rosenson
Mar 28, 2008·Expert Opinion on Drug Metabolism & Toxicology·John R Crouse
Sep 14, 2007·Scandinavian Cardiovascular Journal : SCJ·Ole FrøbertUlf Simonsen
Oct 4, 2005·Current Medical Research and Opinion·Ewoud ter AvestAnton F H Stalenhoef
Feb 3, 2011·Annals of Medicine·Tommaso Gori, Thomas Münzel
May 17, 2011·European Journal of Internal Medicine·Murat KoksalTevfik Sabuncu
Feb 1, 2011·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Hiroshi HagiwaraYasuo Katayama
May 18, 2010·Journal of the American Society of Hypertension : JASH·Simona M HogasAdrian Covic
Apr 27, 2010·Clinical Biochemistry·Lyudmila G Vladimirova-Kitova, Tania Deneva-Koycheva
Jan 12, 2010·Journal of the Neurological Sciences·Yasuhiro NishiyamaYasuo Katayama
May 5, 2009·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Tsukasa NakamuraSho-ichi Yamagishi
Nov 1, 2008·Diabetes Research and Clinical Practice·Katarzyna KrzyzanowskaGuntram Schernthaner
Sep 13, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Prabath W B NanayakkaraYvo M Smulders
Apr 25, 2007·Néphrologie & thérapeutique·Jan T Kielstein, Danilo Fliser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.